Amgen to repay term loan credit agreement debt via new note offerings

By Tali Rackner

Norfolk, Va., Aug. 10 – Amgen Inc. plans to repay borrowings under its term loan credit agreement with the proceeds from four new senior note offerings, according to a 424B3 filing with the Securities and Exchange Commission.

As of June 30, there were $1,725,000,000 of loans outstanding under the term loan credit agreement.

Initial interest is Libor plus 100 basis points, based on the company’s long-term credit ratings.

Proceeds will also be used to repurchase shares of common stock and for general corporate purposes.

Amgen is a Thousand Oaks, Calif., manufacturer and marketer of human therapeutics based upon advances in cellular and molecular biology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.